Evaluating the Role of the Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy

Trial Profile

Evaluating the Role of the Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2015

At a glance

  • Drugs Boceprevir (Primary) ; Peginterferon; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 May 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 10 Dec 2013 Planned end date changed from 1 Feb 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
    • 26 Jun 2012 Planned End Date changed from 1 Feb 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top